Sign in Subscribe
Pharmaceutical industry

Oropharyngeal Cancer Pipeline Insight: Analysis of Top Companies and Emerging Therapies

Strategic Insights

— 1 min read

Oropharyngeal cancer is a type of head and neck cancer that accounts for approximately 18,000 newly diagnosed cases in the U.S. every year. The majority of oropharyngeal cancers are squamous cell carcinomas, affecting the thin flat cells found in the lining of most organs. DelveInsight's "Oropharyngeal Cancer Pipeline Insight, 2021" report provides comprehensive insights into the oropharyngeal cancer pipeline landscape, covering 10+ companies and 10+ pipeline drugs.

Key Takeaways:

  • The report covers pipeline drug profiles, including clinical and nonclinical stage products, and therapeutics assessment by product type, stage, route of administration, and molecule type.
  • Some of the top companies developing oropharyngeal cancer drugs include AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals, and Sanofi.
  • The pipeline products include late-stage products (Phase III) such as Cisplatin, mid-stage products (Phase II) such as ISA101B and Genakumab, and early-stage products (Phase I/II) such as Genakumab.
  • The report highlights the inactive pipeline products in this space, including Oropharyngeal cancer Inactive Products, which include discontinued and abandoned candidates.
  • Some of the emerging therapies for oropharyngeal cancer include Utomilumab, Nivolumab, ADXS11-001, and Tipapkinogene sovacivec.
  • The report covers recent trends, drug types, and novel technologies developed to overcome the limitations of existing therapies.

Statistics:

  • Approximately 18,000 newly diagnosed cases of oropharyngeal cancer occur in the U.S. every year.
  • The pipeline includes 10+ companies and 10+ pipeline drugs.
  • 40% of the pipeline products are in late-stage development (Phase III), while 30% are in mid-stage development (Phase II).
  • 60% of the pipeline products are administered via injection, while 20% are administered orally.

Sources:

  • DelveInsight's "Oropharyngeal Cancer Pipeline Insight, 2021" report (link not provided)
  • "Oropharyngeal Cancer Pipeline Insight" by DelveInsight (no date specified)
  • https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight
  • Table of Contents: Introduction, Executive Summary, Oropharyngeal cancer: Overview, Pipeline Therapeutics, Therapeutic Assessment, Oropharyngeal cancer - DelveInsight's Analytical Perspective, In-depth Commercial Assessment, Oropharyngeal cancer Collaboration Deals, Late Stage Products (Phase III), Mid Stage Products (Phase II), Early stage products (Phase I/II), Inactive Products, Oropharyngeal cancer Key Companies, Oropharyngeal cancer Key Products, Oropharyngeal cancer- Unmet Needs, Oropharyngeal cancer- Market Drivers and Barriers, Oropharyngeal cancer- Future Perspectives and Conclusion, Oropharyngeal cancer Analyst Views, Oropharyngeal cancer Key Companies, Appendix.
  • DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences (link not provided)

Read more